Business Context and Reporting Period
Company: Spectral AI, Inc. (MDAI)
Filing Type: Form 8-K (Current Report)
Date of Report: March 21, 2025
Reporting Period: Events occurring on March 21, 2025, with a press release issued March 24, 2025.
The Company, an emerging growth company incorporated in Delaware, reported the completion of a registered direct offering of common stock and warrants, alongside a concurrent debt financing transaction.
Key Financial Metrics and Transaction Details
Equity Offering
- Shares Issued: 2,076,923 shares of Common Stock.
- Offering Price: $1.30 per share.
- Warrants Issued: 2,076,923 warrants in a concurrent private placement.
- Warrant Exercise Price: $1.80 per share.
- Gross Proceeds: $2,700,000 (combined equity and warrant sales, before fees).
- Use of Proceeds: Working capital and general corporate purposes.
Debt Financing
- Lender: Avenue Venture Opportunities Fund II, L.P. (Avenue Capital Group).
- Total Commitment: Up to $15.0 million.
- Initial Drawdown: $8.5 million.
- Maturity Date: March 1, 2028.
- Interest Rate: Variable, greater of (Prime Rate + 5.25%) or 12.75%.
- Payment Terms: Interest-only for at least 15 months (extendable to 24 months upon milestone achievement).
- Warrant Coverage: 8.5% of total funding commitment.
- Warrant Exercise Price: Lower of $1.66 (5-day VWAP) or the lowest bona-fide equity price paid between March 21, 2025, and December 31, 2025.
Placement Agent Fees
- UK Agent (SP Angel): 7.00% of gross proceeds from UK Offering plus expense reimbursement.
- US Agent (Dominari): $50,000 flat fee.
Material Changes and Conditions
The filing details significant capital structure changes via the simultaneous equity and debt transactions. Key conditions and restrictions include:
- Lock-up Period: The Company is restricted from issuing Common Stock or equivalents for 180 days, with an exception for issuances generating net proceeds of at least $7,000,000.
- Tranche 2 Contingency: The remaining $6.5 million debt commitment is contingent upon:
- U.S. FDA clearance of the Company's DeepView System.
- Completion of an additional $7.0 million equity raise.
- Collateral: The debt financing is secured by a security interest in substantially all of the Company's assets.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to utilize net proceeds for working capital and general corporate purposes. The debt structure includes milestone-based extensions for the interest-only period, specifically tied to FDA clearance.
Risks and Contingencies:
- Regulatory Risk: Future debt tranches depend on FDA clearance of the DeepView System.
- Dilution Risk: Significant warrant coverage exists in both the equity offering (1:1 ratio) and debt financing (8.5% of commitment).
- Forward-Looking Statements: The filing contains forward-looking statements regarding the completion of offerings and use of proceeds, subject to uncertainties and risks detailed in the Company's Form 10-K.
Unusual Items: The filing does not disclose specific revenue, profit, or cash flow metrics for a reporting period, as this is a transactional 8-K rather than a periodic financial report.
Investor Verification Checklist
- Verify the exact net proceeds after deducting placement agent fees and transaction expenses.
- Confirm the status of the FDA clearance for the DeepView System, which is a condition for the $6.5 million debt tranche.
- Review the full text of the Loan and Security Agreement (Exhibit 10.5) for specific covenants and default provisions.
- Monitor the 180-day lock-up period restrictions on future equity issuances.
- Assess the impact of the 8.5% warrant coverage on the debt financing on future share dilution.